Home | Contact Us

Roskamp Institute Patients, Families and Friends Healthcare Professionals Clinical Operations
Roskamp Institute
About Us How to Help News Careers PhD Program Better science. Real discovery.

Clinical Trials Division

The Clinical Trials Division (CTD) is dedicated to the process of pharmaceutical research. The division works closely with the diagnostic clinic to ensure that individuals suffering with Alzheimer’s disease have access to the most up-to-date clinical studies offered by the scientific community working to cure this illness. The CTD takes great pride in its efforts to bring more choices and options to physicians and patients.

  • Roskamp Institute Clinical Trials Experience

Under the leadership of the Institute’s Scientific Director, Michael Mullan, MBBS, Ph.D., along with our clinical investigative team headed by Andrew Keegan, MD, a renowned neurologist, Roskamp has extensive expertise in a multitude of therapeutic areas and phases of pharmaceutical/nutraceutical clinical research. Our clinical research coordinators and nurses, many of whom are certified, are highly experienced in all aspects of clinical trials including regulatory issues, recruitment, and accurate record maintenance. Our goal is to provide excellent trial-related patient care, while meeting contract goals and sponsor timelines. Our research is conducted with strict adherence to Federal Drug Administration (FDA), International Conference of Harmonization (ICH), Good Clinical Practice (GCP) and HIPPA guidelines.

We perform primarily phase II - IV clinical research studies. Specific areas of study include:

For more information on clinical trials, contact:

Roskamp Institute Clinical Trials
2040 Whitfield Avenue
Sarasota, FL 34243

Phone: 941-256-8018
Fax: 941-756-3681

Email: Clinical Trials Division

Roskamp Institute Memory Clinic
2040 Whitfield Avenue
Sarasota, FL 34243

Phone: 941-256-8018
Fax: 941-756-3681

Email: Clinical Trials Division

Top | Home



 

 

 

 


“We aim to offer the latest available clinical trials to those patients wishing to avail themselves of new research options.”
- Dr. Michael Mullan